Addiction, Anhedonia, and Comorbid Mood Disorder. A Narrative Review

Destoop, Marianne; Morrens, Manuel; Coppens, Violette; Dom, Geert

doi:10.3389/fpsyt.2019.00311

Cited by 65 publications

(42 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several animal studies show that BDNF deficiency reduces sucrose preference, a loss of sensitivity to reward which has been suggested to model anhedonia (45)(46)(47)(48). Anhedonia is a core symptom of depression, and also plays an essential role in addictive disorders (49,50). In our sample, peripheral BDNF levels were indeed specifically related with self-reported anhedonia levels in the combined sample.…”

Section: Discussionsupporting

confidence: 59%

Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression

et al. 2020

View full text Add to dashboard Cite

Background: Alcohol Use Disorder (AUD) and depressive disorder often co-exist and have a shared heritability. This study aimed to investigate Brain-Derived Neurotrophic Factor (BDNF) and three Cell Adhesion Molecules (CAMs) as transdiagnostic biomarkers in AUD and depression co-morbidity. Methods: In a cross-sectional study, patients with AUD (n=22), AUD and depression (n=19), and healthy controls (n=20) were examined. Depression and anxiety severity were assessed using the Hamilton Depression Rating Scale and the Hamilton Anxiety Rating Scale. Anhedonia, alcohol use and dependence, craving, and social adaptation were assessed through self-report questionnaires. BDNF and CAM concentrations in peripheral serum were measured after overnight fasting using a Luminex assay. After controlling for age and gender, biomarker levels were compared across groups. The association between biomarker concentrations and symptom severity scales were explored using correlation and multiple regression analyses. Results: BDNF and Neuronal CAM were lower in patients with AUD with and without depression compared to healthy controls. No differences were observed for Vascular CAM-1 and Interstitial CAM-1. BDNF correlated negatively with anhedonia levels. BDNF, age and gender together explained 21% of variability in anhedonia levels. Conclusion: This pilot study suggests that peripheral levels of BDNF and NCAM might be reduced in AUD with and without comorbid mood disorder. Since low BDNF levels were

show abstract

Section: Discussionsupporting

confidence: 59%

Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression

et al. 2020

View full text Add to dashboard Cite

show abstract

“…An alternative-or complementary-hypothesis can be found in the described deficits in the reward system's wanting, i.e., the motivating effect of the anticipatory pleasure before a reward is "consummated". Both substance use and psychotic disorders have been linked to motivational anhedonia, while consummatory pleasure ("liking") appears to be more intact [44,45]. The high frequency of reinforcement in CM might thus help to compensate for the motivational deficits of patients, increasing the chance of behavioral change.…”

Section: Discussionmentioning

confidence: 99%

Meta-Analysis on the Effect of Contingency Management for Patients with Both Psychotic Disorders and Substance Use Disorders

Destoop

Docx

Morrens

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

Background: Substance use disorders (SUD) are highly prevalent among psychotic patients and are associated with poorer clinical and functional outcomes. Effective interventions for this clinical population are scarce and challenging. Contingency management (CM) is one of the most evidence-based treatments for SUD’s, however, a meta-analysis of the effect of CM in patients with a dual diagnosis of psychotic disorder and SUD has not been performed. Methods: We searched PubMed and PsycINFO databases up to December 2020. Results: Five controlled trials involving 892 patients were included. CM is effective on abstinence rates, measured by the number of self-reported days of using after intervention (95% CI −0.98 to −0.06) and by the number of negative breath or urine samples after intervention (OR 2.13; 95% CI 0.97 to 4.69) and follow-up (OR 1.47; 95% CI 1.04 to 2.08). Conclusions: Our meta-analysis shows a potential effect of CM on abstinence for patients with SUD and (severe) psychotic disorders, although the number of studies is limited. Additional longitudinal studies are needed to confirm the sustained effectivity of CM and give support for a larger clinical implementation of CM within services targeting these vulnerable co-morbid patients.

show abstract

“…Animal and human studies were the focus in the paper of anhedonia as a transdiagnostic symptom. Anhedonia is a core symptom in depression and it is also involved in addictive disorders [ 74 ]. In this sense, dysregulation of the reward system and alterations in ventral extrapyramidal circuits were described in both disorders [ 75 , 76 ].…”

Section: Discussionmentioning

confidence: 99%

Alcohol Induced Depression: Clinical, Biological and Genetic Features

Farré

Tirado

Spataro

et al. 2020

JCM

View full text Add to dashboard Cite

Background: In clinical practice, there is the need to have clinical and biological markers to identify induced depression. The objective was to investigate clinical, biological and genetic differences between Primary Major Depression (Primary MD) and Alcohol Induced MD (AI-MD). Methods: Patients, of both genders, were recruited from psychiatric hospitalisation units. The PRISM instrument was used to establish the diagnoses. Data on socio-demographic/family history, clinical scales for depression, anxiety, personality and stressful life events were recorded. A blood test was performed analysing biochemical parameters and a Genome Wide Association Study (GWAS) to identify genetic markers associated with AI-MD. Results: A total of 80 patients were included (47 Primary MD and 33 AI-MD). The AI-MD group presented more medical comorbidities and less family history of depression. There were differences in traumatic life events, with higher scores in the AI-MD (14.21 ± 11.35 vs. 9.30 ± 7.38; p = 0.021). DSM-5 criteria were different between groups with higher prevalence of weight changes and less anhedonia, difficulties in concentration and suicidal thoughts in the AI-MD. None of the genetic variants reached significance beyond multiple testing thresholds; however, some suggestive variants were observed. Conclusions: This study has found clinical and biological features that may help physicians to identify AI-MD and improve its therapeutic approach.

show abstract

Addiction, Anhedonia, and Comorbid Mood Disorder. A Narrative Review

Cited by 65 publications

References 68 publications

Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression

Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression

Meta-Analysis on the Effect of Contingency Management for Patients with Both Psychotic Disorders and Substance Use Disorders

Alcohol Induced Depression: Clinical, Biological and Genetic Features

Contact Info

Product

Resources

About